Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6304-6313

  Kucerova, Lucia ^a   Altanerova, Veronika ^a   Matuskova, Miroslava ^a   Tyciakova, Silvia ^a   Altaner, Cestmir ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; PRODRUG;

ADIPOSE TISSUE; ADIPOSE TISSUE CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER CELL; CANCER GENE THERAPY; COCULTURE; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IN VITRO GENE TRANSFER; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SUICIDE GENE THERAPY; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ADIPOSE TISSUE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; PRODRUGS;

EID: 34447132890     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4024     Document Type: Article

References (40)

1. Bird NC, Mangnall D, Majeed AW. Biology of colorectal liver metastases: A review. J Surg Oncol 2006;94:68-80.
2. Pessino A, Sobrero A. Optimal treatment of metastatic colorectal cancer. Expert Rev Anticancer Ther 2006;6:801-12.
3. Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005;16:349-59.
4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8.
5. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 1997;8:985-1001.
6. Hlavaty J, Hlubinova K, Altaner C. Construction and testing of gene therapy retroviral vector expressing bacterial cytosine deaminase gene. Neoplasma 1999;46:267-76.
7. Gene therapy clinical trials world wide. J Gene Med. Available from: www.wiley.co.uk/genmed/clinical.
8. Kievit E, Nyati MK, Ng E, et al. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. Cancer Res 2000;60:6649-55.
9. Chung-Faye GA, Chen MJ, Green NK, et al. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase, and uracil phosphoribosyltransferase. Gene Ther 2001;8:1547-54.
10. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosphoribosyltransferase fusion gene. Cancer Res 2000;60:3813-22.
11. Ramnaraine M, Pan W, Goblirsch M, et al. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene. Cancer Res 2003;63:6847-54.
12. Hamada H, Kobune M, Nakamura K, et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005;96:149-56.
13. Morizono K, De Ugarte DA, Zhu M, et al. Multilineage cells from adipose tissue as gene delivery vehicles. Hum Gene Ther 2003;14:59-66.
14. Reiser J, Zhang XY, Hemenway CS, Mondal D, Pradhan L, La Russa VF. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 2005;5:1571-84.
15. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effect in a model of Kaposi's sarcoma. J Exp Med 2006;203:1253-47.
16. Nakamizo A, Marini F, Amano T, et al Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005;65:3307-18.
17. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-64.
18. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 2002;62:3603-8.
19. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-603.
20. Hung SC, Deng WP, Yang WK, et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin Cancer Res 2005;11:7749-56.
21. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
22. Stagg J, Lejeune L, Paquin A, Galipeau J. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum Gene Ther 2004;15:597-608.
23. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006;5:755-66.
24. Stoff-Khalili MA, Rivera AA, Mathis JM, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. Epub 2007 Jan 13.
25. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001;7:211-28.
26. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-301.
27. Strem BM, Hicok KC, Zhu M, et al. Multipotential differentiation of adipose tissue-derived stem cells. Keio J Med 2005;54:132-41.
28. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005;33:1402-16.
29. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006;24:150-4.
30. Hlavaty J, Hlubinova K, Altanerova V, Liska J, Altaner C. Treatment of rat gliomas with recombinant retrovirus harboring Herpes simplex virus thymidine kinase suicide gene. Neoplasma 1997;44:342-7.
31. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279-95.
32. Colter DC, Sekiya I, Prockop DJ. Identification of a subpopulation of rapidly self-renewing and multipotential adult stem cells in colonies of human marrow stromal cells. Proc Natl Acad Sci U S A 2001;98:7841-5.
33. Caltagirone S, Rossi C, Poggi A, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 2000;87:595-600.
34. Hilberg F, Aguzzi A, Howells N, Wagner EF. c-jun is essential for normal mouse development and hepatogenesis. Nature 1993;365:179-81.
35. Aboody KS, Najbauer J, Schmidt NO, et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-oncol 2006;8:119-26.
36. Kim SK, Kim SU, Park IH, et al. Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 2006;12:5550-6.
37. Wei J, Blum S, Unger M, et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 2004;5:477-88.
38. Zhu W, Xu W, Jiang R, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006;80:267-74.
39. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43-7.
40. Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma 2005;52:435-40.